Proteinuria

This study tests an experimental drug called VX-147 in adults and children with a genetic form of kidney disease linked to the APOL1 gene. The goal is to see if the drug can reduce protein in the urine and protect kidney function. About 466 participants will receive either VX-147…

This phase 2 trial tests an oral drug called ManNAc in 30 adults with primary focal segmental glomerulosclerosis (FSGS), a kidney disease that causes scarring and protein loss. Participants take ManNAc powder dissolved in water twice daily for 14 weeks. The study aims to see if t…

This study tests the long-term safety of finerenone, a drug that helps control a key system involved in kidney damage, in children aged 1 to 18 with chronic kidney disease and proteinuria. All 100 participants will take finerenone alongside their usual ACE inhibitor or ARB medica…

This study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 30 adults with persistent high pr…

This study tests an experimental drug called iptacopan in 31 children aged 2 to under 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug reduces protein in the urine, a sign of kidney damage, and to check its safety and how t…

This study tests a new drug, JADE101, in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants must be on stable standard care and have a kidney biopsy confirming the dis…

This study tests an experimental drug called praliciguat in 60 adults with a rare kidney disease called FSGS. The goal is to see if it can reduce protein in the urine, a sign of kidney damage. Participants will first receive either the drug or a placebo for 24 weeks, then everyon…

This study tests a drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if it can reduce signs of kidney damage and slow disease progression. Participants must have a recent kidney biopsy and persistent protein in their urine despite stan…

This study tests a drug called sparsentan to reduce high levels of protein in the urine (proteinuria) caused by certain cancer treatments. About 20 adults with cancer who are taking VEGF inhibitors and have developed proteinuria will receive sparsentan for 8 weeks. The goal is to…

This study tests whether adding the drug iptacopan to standard treatment helps people with active lupus nephritis (kidney inflammation caused by lupus) achieve better kidney function and fewer flares. About 240 adults with confirmed lupus nephritis will receive either iptacopan o…

This study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage. Participants will receive the drug through an IV and be monitored for safety …

This Phase 3 trial tests whether iptacopan can reduce protein in the urine and preserve kidney function in people with complement 3 glomerulopathy (C3G), a rare kidney disease. About 98 adults and adolescents will receive either iptacopan or a placebo for 6 to 12 months. The stud…

This study tests a drug called iptacopan in people with a rare kidney disease (IC-MPGN). About 106 adults and teens will receive either iptacopan or a placebo. The main goal is to see if iptacopan reduces protein in the urine and helps preserve kidney function over 18 months.

This study tests whether adding dapagliflozin (a diabetes drug) to standard care reduces protein leakage in the urine of children with hereditary kidney diseases. About 44 children will receive either dapagliflozin plus standard care or standard care alone for 12 weeks, then swit…

This study tests whether montelukast, a common allergy medication, can lower protein levels in urine and improve kidney and blood vessel function in people with type 1 diabetes who have early signs of kidney disease. Inflammation is thought to play a role in diabetic kidney damag…

This study is monitoring the safety and effectiveness of the drug iptacopan (Fabhalta) in 21 Korean adults with paroxysmal nocturnal hemoglobinuria (PNH) or C3 glomerulopathy (C3G). Researchers will track side effects and lab results from routine medical records. The goal is to s…

This early-stage trial tests whether BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 participants with confirmed IgA nephropathy will receive the drug subcutaneously. The main goal is to check for side effects and lab abnormalities.

This study tests whether two diabetes drugs (dapagliflozin and empagliflozin) can help adults with nephrotic syndrome, a kidney condition that causes protein leakage and swelling. About 75 participants will receive either one of these drugs plus standard care, or standard care al…

This study tests whether hydroxychloroquine, a drug already used for lupus, can slow kidney function decline in people with IgA nephropathy (Berger's disease). About 334 adults with biopsy-confirmed IgA nephropathy and high protein in their urine will receive either hydroxychloro…

This study tests whether empagliflozin, a drug already approved for kidney disease in diabetes, can slow kidney damage in people with sickle cell anemia. About 20 adults with sickle cell disease and early signs of kidney trouble will take the drug for 6 months. Researchers will m…

This study tests whether a smartphone app can help people with chronic kidney disease (CKD) follow the latest KDIGO treatment guidelines. Researchers will enroll 80 adults aged 16-30 with CKD who own a smartphone. The app provides reminders, education, and care recommendations to…

This study tests whether dapagliflozin, a drug already used in adults to protect kidneys, can reduce protein leakage in the urine of teenagers with mild chronic kidney disease. Two hundred adolescents aged 14 to 18 will receive either the drug or a placebo for six months. The goa…

This study is testing whether empagliflozin (Jardiance), a drug used for diabetes and chronic kidney disease, is safe for people who have received a kidney transplant. Researchers will enroll 264 veterans and monitor for side effects like infections and changes in kidney function…

This study tests whether combining budesonide (Nefecon) and ambrisentan can reduce protein in the urine and preserve kidney function in people with IgA nephropathy who are at risk of kidney failure. About 129 adults will take both pills daily for 36 weeks. Researchers will measur…

This study tests whether taking spirulina (a microalgae) or seaweed (Gelidium corneum) supplements for 20 weeks can improve markers of heart health and change gut bacteria in people at high risk for heart disease. The trial includes 150 adults aged 50 or older with conditions lik…

This study aims to find out why people with diabetes often have lower vitamin C levels in their blood. Researchers will measure vitamin C in blood, urine, and cells from 5,000 adults with and without diabetes. They will also look at genes that control vitamin C transport. The goa…

This research study follows 500 adolescents with type 2 diabetes to understand why some develop kidney problems. Researchers are looking at biological factors like blood sugar and blood pressure, as well as psychological and social factors such as stress, mental health, and pover…

This study will track 1,200 adults in semi-rural Tanzania to find out how common chronic kidney disease (CKD) is and what factors increase the risk. Participants will have blood and urine tests at the start, after 90 days, and again after one year. The goal is to create better wa…

This study is looking at 300 people with type 2 diabetes who have high levels of protein in their urine, a sign of kidney trouble. Researchers will take small samples of kidney tissue (biopsies) and analyze blood, urine, and stool to find patterns that could improve diagnosis and…

This study is looking at children ages 7 to 18 who have been newly diagnosed with high blood pressure. Researchers want to understand how certain hormones in the body, like angiotensin-(1-7), may contribute to damage in the heart, kidneys, and blood vessels. Over two years, they …

This study aims to find out how common high blood pressure is in children and teenagers (ages 12-17) who are at risk for autosomal dominant polycystic kidney disease (ADPKD) because a parent has it. Researchers will use MRI scans and genetic tests to detect early signs of the dis…

This study looks at why some kidney transplant patients, especially those with a kidney disease called FSGS, develop protein in their urine again after surgery. Researchers will examine blood and kidney tissue samples taken before and after the transplant to find the cause. The g…